TO: Vermont Health Care Providers and Health Care Facilities  
FROM: Dr. Mark Levine, Commissioner of Health

Updated guidance for administering COVID-19 therapies, Evusheld and Sotrovimab

BACKGROUND:

Emergency Use Authorizations (EUAs) for two monoclonal antibody therapies have recently been updated.

- As of February 24, 2022, the dosing for Evusheld has been updated:
  - The initial dosage of Evusheld is now 300 mg of tixagevimab and 300 mg cilgavimab administered as two consecutive intramuscular injections.
  - For patients who received a dose of Evusheld prior to February 24, 2022, providers should schedule these patients to receive additional doses (tixagevimab 150 mg and cilgavimab 150 mg).

- As of February 23, 2022, the duration of infusion and the timing of administration of sotrovimab has changed:
  - Administer sotrovimab 500 mg intravenously over 15 minutes for 50 mL infusion bag OR over 30 minutes for 100 mL infusion bag.
  - Sotrovimab should be given within seven days of symptom onset (previously 10 days).

REQUESTED ACTION:

Be familiar with the updated Emergency Use Authorizations for Evusheld and sotrovimab.

- Evusheld EUA
- Sotrovimab EUA

View a side-by-side comparison of all available COVID-19 outpatient therapies.

For a list of updated sites, please use this tool to locate available therapeutics near you.

If you have any questions, please contact the HAN Coordinator at 802-859-5900 or vthan@vermont.gov.

HAN Message Type Definitions
Health Alert: Conveys the highest level of importance; warrants immediate action or attention.
Health Advisory: Provides important information for a specific incident or situation may not require immediate action.
Health Update: Provides updated information regarding an incident or situation; unlikely to require immediate action.
Info Service Message: Provides general correspondence from VDH, which is not necessarily considered to be of an emergent nature.